Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02449291 · ClinicalTrials.gov registry record · Phase 3
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
A Phase 3 study, sponsored by Acacia Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 568
- Enrollment target
NCT02449291 is a Phase 3 study that has completed, run by Acacia Pharma. The registered enrollment target is 568 participants.
The verdict
NCT02449291, a Phase 3 study, has completed, sponsored by Acacia Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 568 participants
- Enrollment target
Study Summary
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV prophylaxis.
Interventions
- DRUG Placebo
- DRUG APD421
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 568 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02449291
The ClinicalTrials.gov registry entry for NCT02449291 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 568 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acacia Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02449291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02449291 about?
NCT02449291 is a clinical study titled "Study of APD421 as PONV Treatment (no Prior Prophylaxis)". Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV prophylaxis.
What is the current status of trial NCT02449291?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 568 participants. The study started on 2015-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02449291?
The interventions under investigation include: Placebo (DRUG), APD421 (DRUG).
Who is sponsoring clinical trial NCT02449291?
This trial is sponsored by Acacia Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.